At the heart of excellent cancer care is clear communication and informed decision-making. Dr. Hasan Murshed and our team are committed to delivering cutting-edge radiation oncology rooted in evidence, compassion, and individualized care. Whether you are a patient seeking answers or a referring physician looking for clarity on clinical strategies, the following FAQs are designed to explain how modern radiation therapy is used to treat a range of cancers, including head and neck, breast, lung, and prostate. We hope these expert insights help you feel confident and supported throughout your care journey.
Head & Neck Cancer
Q: When is definitive radiation preferred over surgery in head & neck cancer?
A: Definitive radiation therapy (often with concurrent systemic therapy) is preferred when organ preservation is a priority, such as in cancers of the oropharynx, larynx, or hypopharynx, or when surgery would result in significant functional morbidity.
Q: How does HPV status influence radiation strategy?
A: HPV-positive oropharyngeal cancers demonstrate increased radiosensitivity and improved prognosis, allowing for consideration of dose de-escalation strategies in select, clinical trial–supported settings.
Q: What imaging is essential for target delineation?
A: Contrast-enhanced CT and MRI are standard for planning. FDG-PET is critical for nodal staging and identifying occult disease, particularly in cases of unknown primary tumors.
Q: How are elective nodal volumes determined?
A: Elective nodal volumes are based on primary tumor site, T and N stage, laterality, and known lymphatic drainage patterns, guided by consensus atlases and historical patterns of failure.
Q: What is the role of adaptive radiation therapy in head & neck cancer?
A: Adaptive radiation therapy is frequently required due to weight loss, tumor regression, and anatomic changes that may compromise target coverage or increase dose to organs at risk.
Breast Cancer
Q: When is hypofractionation preferred in breast radiation?
A: Hypofractionation is the standard of care for most early-stage breast cancers following breast-conserving surgery, with strong evidence supporting equivalent tumor control and toxicity outcomes.
Q: How is regional nodal irradiation (RNI) decided?
A: RNI decisions are guided by nodal involvement, tumor biology, surgical findings, and recurrence risk, particularly in node-positive or high-risk node-negative patients.
Q: What is the role of partial breast irradiation (PBI)?
A: PBI may be appropriate for select low-risk patients, offering a shorter treatment course with acceptable local control when strict selection criteria are met.
Q: How is cardiac and lung dose minimized?
A: Cardiac and lung exposure is minimized using techniques such as deep inspiration breath hold (DIBH), IMRT/VMAT planning, prone positioning when appropriate, and strict adherence to dose constraints.
Q: When is postmastectomy radiation therapy (PMRT) indicated?
A: PMRT is indicated for patients with four or more positive lymph nodes and selectively for those with one to three positive nodes based on tumor biology, margin status, and recurrence risk.
Lung Cancer
Q: When is SBRT the standard of care for early-stage NSCLC? A: Stereotactic body radiation therapy (SBRT) is standard for medically inoperable stage I
non-small cell lung cancer and offers local control comparable to surgery in carefully selected patients.
Q: How is motion management incorporated into lung radiation therapy?
A: Motion management strategies include 4D-CT imaging, internal target volume (ITV) concepts, respiratory gating, or breath-hold techniques. In the absence of these methods, conservative margins are required.
Q: How is concurrent chemoradiation optimized in stage III disease?
A: Optimization balances adequate target coverage with lung, esophageal, and cardiac dose constraints, guided by PET-based staging and evidence-based dose and fractionation schedules.
Q: What is the role of consolidation immunotherapy?
A: Durvalumab following definitive chemoradiation is the standard of care for unresectable stage III NSCLC, improving both progression-free and overall survival.
Q: How are central versus peripheral lung tumors managed differently?
A: Central lung tumors require modified SBRT fractionation to reduce toxicity risk, while peripheral tumors can safely receive more aggressive hypofractionated regimens.
Prostate Cancer
Q: How is risk stratification incorporated into radiatiseeking clarity on clinical strategies, the following FAQs on therapy planning?
A: Risk stratification using T stage, PSA, Gleason grade group, and increasingly genomic classifiers guides dose selection, target volumes, and androgen deprivation therapy (ADT) integration.
Q: When is hypofractionation or ultra-hypofractionation appropriate?
A: Moderate hypofractionation is standard across risk groups. SBRT is appropriate for selected patients with favorable anatomy and reliable motion control.
Q: What is the role of MRI and PSMA PET in treatment planning?
A: MRI improves intraprostatic target delineation, while PSMA PET enhances nodal and metastatic staging, influencing field design and treatment intent.
Q: When should pelvic lymph nodes be included in the radiation field?
A: Pelvic nodal irradiation is considered for high-risk and select unfavorable intermediate-risk patients based on nomogram-predicted nodal involvement.
Q: How is post-prostatectomy radiation timed?
A: Early salvage radiation therapy at low PSA levels is preferred over routine adjuvant therapy, based on modern randomized trials demonstrating equivalent disease control with reduced toxicity.
Q: What outcomes should referring physicians expect?
A: Modern prostate radiation therapy provides excellent biochemical control with low rates of severe genitourinary and gastrointestinal toxicity, particularly when using image guidance and advanced planning techniques.
Questions? Contact Dr. Murshed:
Hasan Murshed, M.D.
2900 Hwy 77 S. Lynn Haven, FL 32444
+1 850-481-1687